| ID | 1011 |
| Name of the vaccine | Tdvax |
| Microbe | Bacteria |
| Disease name | Diphtheria |
| Name of bacteria | Corynebacterium diphtheriae |
| Type of vaccine | Toxoid |
| Nucleic acid content | DNA |
| Age | 7 years and older |
| Description of the vaccine | Tetanus and Diphtheria Toxoids Adsorbed (Td vaccine). |
| Name of the manufacturer | MassBiologics |
| Name of the manufacturing country | United States |
| Year of manufacture | 2018 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive bacillus. |
| Efficacy | 50% had antitoxin concentrations of 0.01 or greater after 2 doses of Tdvax in primary series. In booster doses, all achieved an antitoxin titer of 0.01 units/mL or higher. |
| Vaccine formulation | Sterile vaccine |
| Dosage | Primary Immunization - Three 0.5 mL doses.
Routine Booster - in children 11-12 years of age and every 10 years. |
| Mechanism of action | Serum diphtheria antitoxin level of 0.01 IU/mL provides lowest level giving some degree of protection. |
| Route of administration | Intramuscular |
| Indications | Active immunization for the prevention of tetanus and diphtheria. |
| Export | Distributed by Grifols USA |
| Approval | US FDA |
| Adjuvant | Aluminium adjuvant |
| Repurposing | For tetanus also. |
| Side effects of vaccine | Pain, tenderness, erythema, induration, pruritis, swelling and warmth, peripheral oedema, pyrexia, malaise, dizziness, headache, convulsions, myalgia, musculoskeletal stiffness or pain, arthralgia, rash, nausea and Cellulitis. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/76430/download |
| Other name | NA |
| Additional Links | NA
|